Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables. Read More
Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors. Read More
Lilly’s oral GLP-1 pill cuts blood sugar and weight without injections—Here’s what the breakthrough data shows
Lilly’s oral GLP-1 drug orforglipron showed strong A1C and weight loss results in Phase 3—find out how it could change diabetes care worldwide. Read More